Pfizer updates Acura on Oxecta commercialization plans
US pharma behemoth Pfizer (NYSE: PFE) has commenced executing its commercialization plan for Oxecta (oxycodone HCl, USP) tablets CII in the USA, which was licensed from Acura Pharmaceuticals (Nasdaq: ACUR) by now Pfizer subsidiary King Pharma.
Acura is eligible to receive tiered royalties ranging from 5% to 25% on net sales of Oxecta. The royalties commence on the first anniversary of the first commercial sale of the drug which Acura does not expect to occur during 2011.
After a significant delay, Pfizer and Acura finally received marketing approval from the US Food and Drug Administration for Oxecta, a tamper-resistant formulation of oxycodone, in the summer, triggering a $20 million milestone to Acura (The Pharma Letter June 21). Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze